Brief: Verastem Oncology Doses First Patient In Target-D 203 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor For Kras G12d-Mutated Metastatic Colorectal Cancer
28/07/2026 23:33
BRIEF-Verastem Oncology Doses First Patient In Target-D 203 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor For Kras G12d-Mutated Metastatic Colorectal Cancer July 28 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 203 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VERSUS-7375 ORAL KRAS G12D (ON/OFF) INHIBITOR FOR KRAS G12D-MUTATED METASTATIC COLORECTAL CANCER
VERASTEM - INITIATES TREATMENT IN ALL THREE TARGET-D PHASE 2 TRIALS
Source text: ID:nBw72Pczza
Further company coverage: VSTM.O
((((Reuters.Briefs@thomsonreuters.com;));))